Treats Stage III colon cancer as a single agent. ANDA 202593, held by Accord Hlthcare. Capecitabine.
As of Nov 16, 2026, ANDA 202593 (Capecitabine), held by Accord Hlthcare, was first approved by FDA on Apr 23, 2015, with 7 approved supplements and 0 published complete response letters.
Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. Breast Cancer treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 23, 2015 | Original application | Approved |
| Capecitabine150MG · tablet;oral | Capecitabine | Rx |
| Capecitabine500MG · tablet;oral | Capecitabine | Rx |
| Jun 9, 2026 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jun 9, 2026 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jun 9, 2026 | Supplement 10Labeling · Standard review | Approved | None posted |
| Jun 9, 2026 | Supplement 11Labeling · Standard review | Approved | None posted |
| Jun 9, 2026 | Supplement 12Labeling · Standard review | Approved | None posted |
| Jun 9, 2026 | Supplement 17Labeling · Standard review | Approved | None posted |
| Apr 4, 2016 | Supplement 1Manufacturing | Approved | None posted |
| Apr 23, 2015 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters